1cP-MiPLA (1-cyclopropanoyl-MiPLA) is a synthetic psychedelic of the lysergamide family and the N1-cyclopropanoyl ester of MiPLA (N-methyl-N-isopropyl lysergamide). By structural analogy with other 1-acyl lysergamide prodrugs such as 1cP-LSD, 1cP-MiPLA is believed to function as a prodrug for MiPLA, with esterase-mediated cleavage of the cyclopropanoyl group releasing the pharmacologically active MiPLA following ingestion.
MiPLA itself is an unusual lysergamide featuring N,N-methyl-isopropyl amide substitution rather than the diethyl amide group of LSD, producing a somewhat shorter-acting and reportedly more clarity-oriented psychedelic experience. Community experience with 1cP-MiPLA, while limited compared to more widely used analogs, describes an experience that is noticeably shorter than LSD (4–7 hours), somewhat more introspective and mentally clear, and less visually overwhelming. This character has made it of interest to users who find LSD's long duration difficult to manage.
1cP-MiPLA is among the less well-documented lysergamide research chemicals. Very few formal experience reports exist, and its pharmacology has not been directly studied in humans. Users are essentially treating it as a proxy for MiPLA, applying the prodrug logic that has been confirmed for 1cP-LSD and inferred for other 1-acyl compounds. This means that dosing, duration, and effects are substantially uncertain, and extreme caution with initial doses is warranted.
As with all research chemical lysergamides, testing with Ehrlich reagent is essential before use, and those with personal or family history of psychosis should not use this compound. The overall risk profile is assumed to parallel other lysergamide prodrugs but has not been formally characterized.
Safety at a Glance
High Risk- Dosing guidance is based on sparse community data and extrapolation from MiPLA experience:
- Threshold: 50–75 μg
- Toxicity: Acute Toxicity No formal toxicological data exist for 1cP-MiPLA or its parent compound MiPLA in humans. By structural...
- Overdose risk: Overdose The LD50 of 1cP-MiPLA is unknown. Adverse psychological reactions are common especially ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
The onset is so gentle you might miss it entirely. Twenty or thirty minutes pass and then you notice that the pattern on the curtains has become slightly more interesting, that the sunlight on the table has a quality you cannot quite name. 1cP-MiPLA operates at the quiet end of the psychedelic spectrum, a whisper where its lysergamide cousins speak at conversational volume or shout.
Physically, the experience is remarkably benign. There is a mild stimulation, enough to make a walk appealing but not enough to create restlessness. A faint warmth gathers in the chest and face. Some report a very slight tingling in the extremities. The body load that accompanies many lysergamides is almost entirely absent here, leaving a clean, transparent feeling, as though your sensory apparatus has been gently recalibrated rather than overwhelmed.
At what passes for a peak, the changes remain subtle but unmistakable. Colors gain a faint luminosity. Music becomes slightly more textured, more emotionally resonant; you notice harmonics and timbral details that normally sit below the threshold of attention. There is an enhancement of aesthetic appreciation that extends to ordinary objects, the curvature of a coffee mug, the way shadow falls across a bookshelf. Cognitively, thoughts flow with slightly increased fluidity, and creative associations come more readily, but there is no psychedelic confusion, no conceptual avalanche. Mood lifts gently into a space of quiet contentment.
The offset is as gradual as the onset. Effects taper over three to four hours, leaving almost no residual disruption. There is no harsh landing, no period of exhausted overstimulation. You simply find, at some point in the late afternoon or evening, that the subtle enhancement has dissolved and the world has returned to its default settings. The experience reads less like a psychedelic journey and more like a minor adjustment to the tuning of consciousness, a cleaning of perceptual lenses that leaves everything slightly brighter for a while.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(24)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(19)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(2)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
1cP-MiPLA is believed to act as a prodrug for MiPLA (N-methyl-N-isopropyl lysergamide), with the cyclopropanoyl group at the N1 position being cleaved by esterase enzymes following administration. The resulting MiPLA acts as a partial agonist at serotonin 5-HT2A receptors, the primary pharmacological target of classical psychedelics. This disrupts normal hierarchical sensory processing in the prefrontal cortex, producing the altered perception, enhanced associative thinking, and emotional modulation characteristic of the lysergamide class.
Receptor Targets
Based on the structure of MiPLA and close analogy to other lysergamides:
- 5-HT2A receptors — primary target; partial agonism underlies psychedelic effects
- 5-HT1A receptors — partial agonist; may contribute to introspective, meditative quality reported for MiPLA-type compounds
- 5-HT2C receptors — affinity expected; role in anxiogenic aspects
- Dopamine D2 receptors — moderate affinity; contributes to stimulation and mood
- α-adrenergic receptors — sympathomimetic effects including mydriasis and mild tachycardia
The N,N-methyl-isopropyl amide substitution of MiPLA, relative to LSD's diethyl amide, alters steric bulk in the amide binding pocket and likely produces modest changes in receptor binding kinetics, contributing to the reportedly shorter duration and different character of MiPLA-family compounds.
Pharmacokinetics
Following oral administration, cyclopropanoyl ester hydrolysis is expected to occur in the gut and bloodstream, generating free MiPLA. Based on the established kinetics of 1cP-LSD prodrug conversion, the onset may be slightly delayed relative to MiPLA itself (45–90 minutes). Duration of effects for MiPLA is reported in the range of 4–7 hours — substantially shorter than LSD's 8–12 hours — likely attributable to faster receptor dissociation kinetics or more rapid metabolism. No human pharmacokinetic data exist for 1cP-MiPLA.
Tolerance
Cross-tolerance with all serotonergic psychedelics is expected. Functional tolerance develops within 24–48 hours of use and reverses over 5–7 days.
Detection Methods
Urine Detection
1cP-MiPLA and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for 1cP-MiPLA are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
1cP-MiPLA is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for 1cP-MiPLA. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
1cP-MiPLA is among the more recently introduced lysergamide prodrug analogs, appearing in the research chemical market as part of the broader wave of 1-acyl lysergamides that emerged after 1cP-LSD gained popularity. It was designed as a legal-by-analogy prodrug of MiPLA, a compound first synthesized and described by Albert Hofmann's group at Sandoz in the mid-20th century as part of systematic ergot alkaloid research.
MiPLA Background
MiPLA itself was synthesized and characterized in early lysergamide structure-activity research, noted for its atypical amide substitution pattern (N-methyl-N-isopropyl rather than diethyl). It attracted renewed interest when the research chemical market began exploring lysergamide diversity in the 2010s.
Legal Status
1cP-MiPLA is not scheduled under international drug conventions but may be subject to analog act prosecution in the United States and specific national laws in various countries. The Psychoactive Substances Act 2016 in the United Kingdom bans it along with all other psychoactive research chemicals. Users should verify current legal status in their jurisdiction.
Harm Reduction
Testing
Use an Ehrlich reagent — a genuine lysergamide compound will turn purple/violet. NBOMe compounds and other dangerous non-indole adulterants will not react. Given the limited availability and non-standardized supply of 1cP-MiPLA, testing is especially critical.
Dosing
Dosing guidance is based on sparse community data and extrapolation from MiPLA experience:
- Threshold: 50–75 μg
- Light: 75–100 μg
- Common: 100–175 μg
- Strong: 175–250 μg
Due to very limited community experience, starting at the low end (75 μg or below) is strongly advisable. The shorter reported duration of MiPLA-family compounds may cause some users to redose prematurely — this is dangerous, as peak effects may not have been reached.
Set and Setting
- As with all lysergamides: approach in a stable mental state, in a familiar and comfortable environment
- A sober trip-sitter is strongly recommended given the limited community knowledge base for this compound
- The shorter duration may be an advantage for users with time or schedule constraints, but should not be an excuse to rush into high doses
Dangerous Combinations
- Lithium — Contraindicated; seizure and cardiac risk across lysergamide class
- MAOIs — Risk of serotonin syndrome
- Tramadol — Lowers seizure threshold
- Cannabis — Risk of amplified anxiety and disorientation
- Stimulants — Increased cardiovascular and psychological intensity
Emergency Protocol
- Benzodiazepines (diazepam 10–20 mg) are the standard harm reduction intervention for acute lysergamide distress
- Change environment, use grounding techniques (cold water, slow breathing, physical contact)
- Call emergency services if any concern about physical safety; report the substance
Toxicity & Safety
Acute Toxicity
No formal toxicological data exist for 1cP-MiPLA or its parent compound MiPLA in humans. By structural and pharmacological analogy to LSD, acute toxicity is expected to be very low. No fatalities directly attributable to 1cP-MiPLA have been reported. The primary risks are psychological, not physiological.
Cardiovascular Effects
Sympathomimetic effects are expected consistent with the lysergamide class: modest heart rate and blood pressure elevation, pupil dilation, and mild vasoconstriction. These are generally well tolerated in healthy individuals. Individuals with cardiovascular disease, arrhythmias, or uncontrolled hypertension should not use lysergamide compounds.
Psychological Risks
- Acute anxiety and panic — The most common adverse event across the lysergamide class. Risk correlates with dose, setting, and personal psychological vulnerability.
- Psychosis induction — Contraindicated in anyone with personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder.
- HPPD — Persistent visual disturbances following hallucinogen use; risk is elevated with repeated use.
Contraindications
- Personal or family history of psychosis or bipolar disorder
- Current use of lithium, MAOIs, antipsychotics, or tramadol
- Cardiovascular disease or uncontrolled hypertension
- Pregnancy or breastfeeding
Overdose
No cases of pharmacological overdose have been documented. Extreme psychological distress and disorientation are the expected presentations. Benzodiazepines are the first-line intervention for acute panic or psychological crisis.
Addiction Potential
not habit-forming
Overdose Information
Overdose
The LD50 of 1cP-MiPLA is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of 1cP-MiPLA.
1cP-MiPLA is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
Austria: 1cP-MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: 1cP-MiPLA is illegal in Germany as of July 2021.
Switzerland: 1cP-MiPLA can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
United States: 1cP-MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelics
MiPLA
EiPLA
LSD
1cP-MiPLA (Isomer Design)
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
1cP-MiPLA is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
Austria: 1cP-MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: 1cP-MiPLA is illegal in Germany as of July 2021.
Switzerland: 1cP-MiPLA can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
United States: 1cP-MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelics
MiPLA
EiPLA
LSD
1cP-MiPLA (Isomer Design)
Experience Reports (1)
Tips (4)
Start with a low dose of 1cP-MiPLA if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of 1cP-MiPLA for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
Set and setting are paramount with 1cP-MiPLA. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
Do not combine 1cP-MiPLA with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
See Also
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 1cP-MiPLA - TripSit Factsheet
TripSit factsheet for 1cP-MiPLA
tripsit - 1cP-MiPLA - Wikipedia
Wikipedia article on 1cP-MiPLA
wikipedia